FINWIRES · TerminalLIVE
FINWIRES

Agios Gets EU Approval for Pyrukynd in Thalassemia

By

Agios Pharmaceuticals (AGIO) said Friday the European Commission granted marketing authorization for Pyrukynd to treat adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia.

The oral therapy received orphan medicinal product designation in the European Union.

The approval was based on results from the two phase 3 clinical trials evaluating the medicine in adults with thalassemia, Agios said.

The company added that its partner, Avanzanite Bioscience, will continue to commercialize and distribute Pyrukynd across Europe.

Price: $28.58, Change: $-0.21, Percent Change: -0.73%

Related Articles

Wire

Zoom Communications Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Zoom Communications (ZM) reported fiscal Q1 adjusted diluted earnings late Thursday of $1.55 a share, up from $1.43 a year earlier.Analysts polled by FactSet expected $1.42.Revenue in the three months ended April 30 rose to $1.24 billion from $1.17 billion a year earlier.Analysts surveyed by FactSet expected $1.22 billion.The company expects fiscal Q2 non-GAAP diluted EPS of $1.45 to $1.47 on revenue of $1.265 billion to $1.27 billion. Analysts expect EPS of $1.49 on revenue of $1.266 billion.Zoom expects full-year non-GAAP diluted EPS of $5.96 to $6 on revenue of $5.08 billion to $5.09 billion, up from the prior outlook of EPS of $5.77 to $5.81 on revenue of $5.065 billion to $5.075 billion.Analysts polled by FactSet expect EPS of $5.88 on revenue of $5.075 billion.Zoom shares rose 7% in after-hours trading.

$ZM
Wire

Deckers Outdoor Fiscal Q4 Earnings Fall, Revenue Rises; Sets Fiscal 2027 Guidance

Deckers Outdoor (DECK) reported fiscal Q4 earnings late Thursday of $0.96 per diluted share, down from $1.00 a year earlier.Analysts polled by FactSet expected $0.83.Net sales for the quarter ended March 31 were $1.12 billion, up from $1.02 billion a year earlier.Analysts surveyed by FactSet expected $1.09 billion.The company expects fiscal 2027 earnings of $7.30 to $7.45 per share on net consolidated sales of $5.86 billion to $5.91 billion. Analysts polled by FactSet expect $7.35 and $5.82 billion, respectively.The company said its board has approved an increase of $3.5 billion to the stock repurchase authorization, which brings total outstanding authorization to about $5 billion.

$DECK
Wire

Earnings Flash (TTWO) Take-Two Interactive Software Posts Fiscal Q4 Per Share Loss -$0.32, vs. FactSet Est of $-0.57 Loss

Earnings Flash (TTWO) Take-Two Interactive Software Posts Fiscal Q4 Per Share Loss -$0.32, vs. FactSet Est of $-0.57 Loss

$TTWO